Search Results

DEBATE: Drug of choice for exon 19 del EGFR mutant NSCLC - Afatinib

DEBATE: Drug of choice for exon 19 del EGFR mutant NSCLC - Afatinib

DEBATE: Drug of choice for exon 19 del EGFR mutant NSCLC - Any EGFR TKI

DEBATE: Drug of choice for exon 19 del EGFR mutant NSCLC - Any EGFR TKI

Dr. Chachoua on Afatinib for Exon 19 Mutation in Lung Cancer

Dr. Chachoua on Afatinib for Exon 19 Mutation in Lung Cancer

Dr. West on FDA Approval of Afatinib in NSCLC With Rare EGFR Mutations

Dr. West on FDA Approval of Afatinib in NSCLC With Rare EGFR Mutations

Adjuvant therapy for EGFR mutant NSCLC

Adjuvant therapy for EGFR mutant NSCLC

[lung] Afatinib vs cisplatin chemo for EGFR+ lung cancer: survival data from LUX-Lung trials

[lung] Afatinib vs cisplatin chemo for EGFR+ lung cancer: survival data from LUX-Lung trials

Dr. Govindan on the Future of EGFR-Mutant NSCLC

Dr. Govindan on the Future of EGFR-Mutant NSCLC

EGFR TKIs for Upfront Treatment of NSCLC

EGFR TKIs for Upfront Treatment of NSCLC

EGFR Mutations in NSCLC

EGFR Mutations in NSCLC

TKI-resistant EGFR-mutant NSCLC

TKI-resistant EGFR-mutant NSCLC

EGFR Mutations in Patients With Lung Cancer

EGFR Mutations in Patients With Lung Cancer

Side Effect Management With Afatinib

Side Effect Management With Afatinib